A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

To be considered for this study, you would need to be a woman, aged 18 or over, who has been diagnosed with cervical cancer that has either come back or spread to other parts of your body. Importantly, your cancer would need to have progressed after you've already had at least one course of chemotherapy (which might have included a drug called bevacizumab) and also a specific type of immunotherapy.

Doctors would also need to be able to measure your cancer to track how it responds to treatment. You would need to be generally well enough to take part, as assessed by your doctor. The study also requires a recent tissue sample of your cancer. There are specific health requirements regarding HIV, hepatitis B, and hepatitis C, requiring these conditions to be well-managed if present. You should not have severe nerve damage (neuropathy) or certain severe eye conditions.

As a participant in this study, you would first undergo a series of health checks to confirm your eligibility. If you meet the criteria, you would either be part of a small safety group or enter the main study where you would be randomly assigned to receive either the new treatment (Sacituzumab Tirumotecan) or a standard treatment chosen by your doctor. These standard treatments could include medications like Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, or Irinotecan. The specific medication would depend on what your doctor feels is most appropriate for you.

Throughout the study, you would attend regular appointments for assessments, blood tests, and scans to monitor your health and how your cancer is responding. The exact number and frequency of visits would be explained to you by the study team. You would receive your assigned medication as part of these visits. The study would continue for as long as the treatment is helping you, or until unacceptable side effects occur, with regular follow-up appointments even after treatment stops to track your long-term health. The total duration of your participation would vary depending on your individual response to treatment.